More Warnings Urged for ADHD Drugs
Posted on: Wednesday, 15 March 2006, 12:00 CST
The U.S. Food and Drug Administration is recommending stronger warnings be used for drugs prescribed to treat attention deficit hyperactivity disorder.
The FDA has been most concerned about reports of psychiatric and cardiovascular risks possibly linked with the drugs, The Wall Street Journal reported Wednesday. A meeting of outside medical experts, who will focus on the issue, is scheduled for next week.
The agency's ADHD psychiatric review team earlier this month said current labeling neither addresses the concerns nor does it clearly state the importance of stopping drug therapy in any patient who develops hallucinations or other signs or symptoms of psychosis or mania during drug treatment of ADHD.
The FDA review found nearly 1,000 reports of psychosis or mania possibly linked to ADHD drugs -- including Adderall, Concerta, Ritalin and Strattera --were received between Jan. 1, 2000, and July 1, 2005.
Another FDA panel last month recommended stronger warnings concerning possible links between the ADHD drugs and heart attacks and strokes.
Source: United Press International
Related Articles
- Report Finds Rising Abuse Of ADHD Drugs
- ADHD Drug Data to Be Reviewed
- eRx Collaborative Boosts Patient Safety With 8,000 Prescriptions Changed in June; Record Number of Electronic Prescriptions Changed As a Result of Drug-Drug and Drug-Allergy Alerts
- Almost All New Drug Approvals Receive FDA Requests for Post-Marketing Studies
- Shire Seeks Approval for Long-Acting ADHD Drug
- More of ADHD Drugs' MO Revealed
- FDA Sets Date for Decision on Shire ADHD Drug
- Psychiatric Side Effects of ADHD Drugs Probed
- FDA Probing ADHD Drugs for Side Effects
- ADHD Drug Prescriptions Vary by ZIP Code
 |
 |
User Comments (0)
RSS Feeds